269 related articles for article (PubMed ID: 7568072)
1. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
Kranz DM; Patrick TA; Brigle KE; Spinella MJ; Roy EJ
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9057-61. PubMed ID: 7568072
[TBL] [Abstract][Full Text] [Related]
2. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
3. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate.
Roy EJ; Cho BK; Rund LA; Patrick TA; Kranz DM
Int J Cancer; 1998 May; 76(5):761-6. PubMed ID: 9610737
[TBL] [Abstract][Full Text] [Related]
4. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
5. Bispecific agents target endogenous murine T cells against human tumor xenografts.
Rund LA; Cho BK; Manning TC; Holler PD; Roy EJ; Kranz DM
Int J Cancer; 1999 Sep; 83(1):141-9. PubMed ID: 10449621
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells.
Spinella MJ; Brigle KE; Sierra EE; Goldman ID
J Biol Chem; 1995 Apr; 270(14):7842-9. PubMed ID: 7713875
[TBL] [Abstract][Full Text] [Related]
7. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
[TBL] [Abstract][Full Text] [Related]
8. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
9. Effect of receptor occupancy on folate receptor internalization.
Bandara NA; Hansen MJ; Low PS
Mol Pharm; 2014 Mar; 11(3):1007-13. PubMed ID: 24446917
[TBL] [Abstract][Full Text] [Related]
10. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
Pan X; Lee RJ
Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines.
Miotti S; Bagnoli M; Ottone F; Tomassetti A; Colnaghi MI; Canevari S
J Cell Biochem; 1997 Jun; 65(4):479-91. PubMed ID: 9178098
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation of the T-cell antigen-specific receptor and its potential role in lectin-mediated cytotoxicity.
Hubbard SC; Kranz DM; Longmore GD; Sitkovsky MV; Eisen HN
Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1852-6. PubMed ID: 3081904
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.
Ross JF; Chaudhuri PK; Ratnam M
Cancer; 1994 May; 73(9):2432-43. PubMed ID: 7513252
[TBL] [Abstract][Full Text] [Related]
14. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.
Thompson S; Dessi J; Self CH
MAbs; 2009; 1(4):348-56. PubMed ID: 20068406
[TBL] [Abstract][Full Text] [Related]
16. Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies.
Barr IG; MacDonald HR; Buchegger F; von Fliedner V
Int J Cancer; 1987 Sep; 40(3):423-9. PubMed ID: 3497884
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
18. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
Pan XQ; Zheng X; Shi G; Wang H; Ratnam M; Lee RJ
Blood; 2002 Jul; 100(2):594-602. PubMed ID: 12091353
[TBL] [Abstract][Full Text] [Related]
19. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.
Kranz DM; Tonegawa S; Eisen HN
Proc Natl Acad Sci U S A; 1984 Dec; 81(24):7922-6. PubMed ID: 6334855
[TBL] [Abstract][Full Text] [Related]
20. Folate-immunoglobulin G as an anticancer therapeutic antibody.
Li H; Lu Y; Piao L; Wu J; Yang X; Kondadasula SV; Carson WE; Lee RJ
Bioconjug Chem; 2010 May; 21(5):961-8. PubMed ID: 20429546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
